(NASDAQ: VOR) Vor Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Vor Biopharma's earnings in 2025 is -$1,664,426,000.On average, 6 Wall Street analysts forecast VOR's earnings for 2025 to be -$352,907,502, with the lowest VOR earnings forecast at -$514,537,427, and the highest VOR earnings forecast at -$89,121,575. On average, 6 Wall Street analysts forecast VOR's earnings for 2026 to be -$44,638,698, with the lowest VOR earnings forecast at -$74,489,675, and the highest VOR earnings forecast at -$12,969,184.
In 2027, VOR is forecast to generate -$7,549,047 in earnings, with the lowest earnings forecast at -$7,324,818 and the highest earnings forecast at -$7,848,019.